Immunology Program

The Alexander Gitlin Lab

Share
Back to top

Research

Alexander Gitlin
Alexander Gitlin, MD, PhD

The Alexander Gitlin Lab studies how inflammatory cell signaling controls the nature and magnitude of inflammation under physiological and disease conditions. Innate immune cells are tasked with integrating diverse molecular signals from both host and pathogen to produce appropriately commensurate inflammatory responses. Whereas insufficient inflammatory responses can lead to immunodeficiency, overexuberant inflammation can cause devastating collateral tissue damage. We study a set of genes that control the balance between cellular signaling and death and whose deficiencies cause a wide spectrum of severe genetic immune diseases in humans. Focusing on this interconnected network of genes, we use genome editing in primary immune cells, in vivo models, biochemistry, proteomics, advanced imaging techniques, and genomic screens to decipher molecular and cellular pathways that govern inflammation and innate immunity.

Publications Highlights

Gitlin AD, Maltzman A, Kanno Y, Heger K, Reja R, Schubert AF, Wierciszewski LJ, Pantua H, Kapadia SB, Harris SF, Webster JD, Newton K, Dixit VM. N4BP1 coordinates ubiquitin-dependent crosstalk within the IκB kinase family to limit Toll-like receptor signaling and inflammation. Immunity. 2024 May 14;57(5):973-986.e7. doi: 10.1016/j.immuni.2024.04.004. Epub 2024 May 1. PMID: 38697117; PMCID: PMC11096006.

Newton K, Gitlin AD. Deubiquitinases in cell death and inflammation. Biochem J. 2022 May 27;479(10):1103-1119. doi: 10.1042/BCJ20210735. PMID: 35608338; PMCID: PMC9162465.

Gitlin AD, Heger K, Schubert AF, Reja R, Yan D, Pham VC, Suto E, Zhang J, Kwon YC, Freund EC, Kang J, Pham A, Caothien R, Bacarro N, Hinkle T, Xu M, McKenzie BS, Haley B, Lee WP, Lill JR, Roose-Girma M, Dohse M, Webster JD, Newton K, Dixit VM. Integration of innate immune signalling by caspase-8 cleavage of N4BP1. Nature. 2020 Nov;587(7833):275-280. doi: 10.1038/s41586-020-2796-5. Epub 2020 Sep 24. PMID: 32971525.

 

View All Publications

People

Alexander Gitlin

Alexander Gitlin, MD, PhD

  • The Gitlin Lab studies the molecular and cellular mechanisms underlying inflammatory cell signaling in health and disease.
  • MD, Weill Cornell Medicine, Medicine (2017)
  • PhD, The Rockefeller University, Immunology (2016)
[email protected]
Email Address
646-888-3755
Office Phone
View physician profile
Physician profile

Members

Julia Ashmead

Administrative Assistant

Tandrila Das

Research Fellow

Yuzuka Kanno

Graduate Student

Rebecca Londoner

Graduate Student

Pia Martindale
Pia Martindale

Research Technician

Joshua Morrison

Graduate Student

Linsey Wierciszewski
Linsey Wierciszewski

Research Technician

Lab Affiliations

Achievements

  • NIH Director's DP5 Early Independence Award (2022-2027)
  • Josie Robertson Investigator (2022-2027)
  • Burroughs Wellcome Fund: Career Award for Medical Scientists (2022)
  • National Institute of Allergy and Infectious Diseases (NIAID) K08: Mentored Clinical Scientist Research Career Development Award (2021)
  • Harold M. Weintraub Graduate Student Award (2016)

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Career Opportunities

Apply now

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Alexander Gitlin discloses the following relationships and financial interests:

  • Eli Lilly and Company
    Equity
  • Genentech
    Professional Services and Activities

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures